


Identification of metabolites: analytical challenges for conducting *in vitro* metabolism characterisation of pesticides




Outline

Introduction

Analytical aspects

Data processing

Conclusions



Why do we need to identify metabolites?


Metabolites can affect the efficacy and safety of potential drugs

- Efficacy
 - The metabolites modulate the efficacy of drugs in the treatment of disease
 - Metabolites may possess pharmacological activity
- Safety
 - Metabolite may be toxic (bioactivation)
 - Active metabolites and reactive metabolites may impact on safety



Pharmaceutical Companies are mandated
by Regulatory Agencies to identify metabolites of NCEs


What is the stage-based need for metabolite identification?



- In discovery stage:
 - Address clearance issues (metabolic hot-spots) leading to short half-life
 - Provide biotransformation pathway information for candidate selection as well as during lead optimisation
 - Generate potential new leads
 - Eliminate compounds that produce potentially reactive metabolites
- In development stage:
 - Determine metabolic pathways in preclinical species and in humans
 - Attempt to model metabolism in humans
 - Ensure that the preclinical species chosen for safety evaluation are adequate
 - Ensure all major metabolites are monitored

Metabolite identification workflow

Continuous and iterative process



Identification confidence







Example	Identification confidence	Minimum data requirements
	Level 1: Confirmed structure by reference standard	MS, MS ² , RT, Reference Std.
	Level 2: Probable structure a) by library spectrum match b) by diagnostic evidence	MS, MS ² , Library MS ² MS, MS ² , Exp. data
	Level 3: Tentative candidate(s) structure, substituent, class	MS, MS ² , Exp. data
	Level 4: Unequivocal molecular formula	MS isotope/adduct
	Level 5: Exact mass of interest	MS

Figure 1. Proposed identification confidence levels in high resolution mass spectrometric analysis. Note: MS² is intended to also represent any form of MS fragmentation (e.g., MS^e, MSⁿ).

LC separation

Samples should be analysed using generic LC conditions to balance adequate retention and reasonable elution times of various metabolites

Co-elution of metabolites should be avoided case of isobaric species and as well as liquid chromatography coupled to UV/radio detection




Metabolite characterisation: Mass spectrometry

Tandem Mass Spectrometry

technique to identify metabolites in complex biological matrices

Equipment

- Triple Quadrupole (QQQ)
- Ion Traps (IT and LIT)
- Q-Orbitrap
- Q-Time Of Fly (TOF)




	A. QQQ-MS	B. IT-MS	C. Q-TOF-MS	D. Orbi-MS
Mass Resolution	low	low	high	high/ultra-high
Sensitivity	Global acquisition Targeted acquisition	1 3 (4)	2 (3) (2) 3	3 (2) 3
Specificity	Global acquisition Targeted acquisition	1 3	(2) 3 (3) 4	(3) 4 4 (5)
Acquisition rate	Global acquisition Targeted acquisition	1 3	(3) 4 (2) 3	3 2
Sum	Global acquisition Targeted acquisition	3 9-10	6 7-9	8-10 7-10

Fig. 2. Scheme of the 4 most used LC-MS technologies: 2 low resolution technologies, triple quadrupole (A: QQQ-MS) and ion trap MS (B: IT-MS) and 2 high resolution technologies, quadrupole-time-of-flight-MS (C: Q-TOF) and quadrupole-orbi-MS (D: Q-orbi); adapted from [12]. The table below allocates a grade according to global or targeted MS performance (1 to 5 points for poor to excellent, respectively). Global acquisition corresponds to high resolution full scan (HR-FS) or data-independent-acquisition (DIA). Targeted acquisition corresponds to SIM (single ion monitoring), SRM (selected reaction monitoring) or product ion scan. Sensitivity, specificity and acquisition rate (scan speed) are considered and points are summed in the last row. **Abbreviations.** CC: collision cell; d: detector; F: flight; FT: Fourier transform; IT: ion trap; O: orbitrap; p: pusher; Q: quadrupole; r: reflectron; Δt : delta of time.

Accurate mass measurement

Metabolite Characterization using Mass Spectrometry




Take advantage of Nature's imperfection!

Resolution and accuracy

Metabolite characterisation using Mass Spectrometry

Resolution

in mass spectrometry, is a measure of the ability to distinguish between two peaks of different mass-to-charge ratio (m/z) in a mass spectrum.



Full Width at Half Maximum (FWHM)
is a way to define resolution in mass spectrometry


$$\text{FWHM} = \frac{485.1270}{0.0532} \sim 9000$$

Accurate Mass Measurement

$$\text{ppm} = \frac{m/z_{\text{Observed}} - m/z_{\text{Theoretical}}}{m/z_{\text{Theoretical}}} (10)^6$$

Accurate mass measurement


Exact Mass can confirm and distinguish
elemental composition for metabolites with the same nominal mass



Obtained using QToF II

Resolution and isotopic distribution

Metabolite characterisation using mass spectrometry



FWHM= 50000

FWHM= 5000

FWHM= 500

Even highest mass accuracy and resolution, however, is not sufficient to determine the unique chemical formula of each ion

Isotope pattern evaluation can be useful to reduce the search space and determine the molecular formula

HR mass spectrometer



ThermoFisher
SCIENTIFIC



SCIEX
Answers for Science.
Knowledge for Life.™



Waters
THE SCIENCE OF WHAT'S POSSIBLE.®



SHIMADZU



Agilent Technologies

HRMS

Q-Orbitrap

QTOF

QTOF

Q-TOF and IT-TOF

Q-TOF

Software

Compound Discoverer™

MetabolitePilot™

UNIFI™


MetID solution

Mass MetaSite


Data Elaboration is the bottleneck of Metabolite Identification

Metabolite characterisation: Mass spectrometry

Acquisition process




Polarity switching in metabolite profiling



It can be advantageous to screen for metabolites using both positive and negative ionization modes.

This is especially true for phase II metabolism which tends to make molecules more polar and often more acidic



Functionality provided by Met ID profiling tools

- Identification of drug and related metabolites as chromatographic peaks from the complex TIC trace
- Assignment of chemical structures for each identified metabolite

Comparison with Control

Biotransformation List

Isotope filtering

Mass Defect Filtering

MSMS acquisition method creation

Formula Prediction

MS/MS Data Interpretation

Linkage to specific Database

Statistical Analyses

Biotransformation list

Parent

Set Biotransformation

Generate List
Expected Metabolite

Output
Expected Metabolites

Comparison with Control

List of putative
metabolites

Table 1 Effects of common phase I metabolic reactions on the mass-spectrometric behavior and retention in comparison with the parent drug

Nominal mass shift (Δ Da)	Metabolic reaction (elemental composition change)	Exact mass shift (mDa)	Examples of relative retention shift ^a	References
–	Azo reduction to amines ($R_1N = NR_2 \rightarrow R_1NH_2 + R_2NH_2$)	–	–	[145]
–14 ^b	Hydrolysis of ester to carboxylic acid ($-C_xH_{2x}$)	–15.7 ^x	–	[106]
–90	Reductive debenzylation ($-C_6H_5$)	–47.0	0.74 [134]	[124]
–78	Reductive debromination ($-Br+H$)	+89.5	–	[113]
–74	Oxidative debenzylation ($-C_6H_5+O$)	–52.0	–	[180]
–68	Loss of CF_3 ($-CF_3+H$)	+12.6	–	[107]
–62	Oxidative debromination ($-Br+OH$)	+84.4	0.39 [17]	[17]
–56	Debutylation ($-C_4H_9$)	–62.6	–	[107]
–45	Hydrolysis of nitrate to alcohol ($-NO_2+H$)	+14.9	–	[113]
	Reductive loss of nitro group ($-NO_2+H$)	+14.9	1.37 [46]	[46, 106]
–44	Decarboxylation ($-CO_2$)	+10.2	–	[106]
–42	Depropylation ($-C_3H_8$)	–47.0	0.73—isopropyl [131]; 0.85, 1.09—propyl [24]	[24, 131]
–36	Loss of HCl ($-HCl$)	+23.3	–	[148]
–34	Reductive dechlorination ($-Cl+H$)	+39.0	–	[148]
–30	Nitro reduction to amine ($-O_2+H_2$)	+25.8	0.75 [144]	[144]
–28	Deethylation ($-C_2H_5$)	–31.3	0.87 [76]	[76]
–25	Reductive loss of nitrile group ($-CN+H$)	+4.8	0.88 [45]	[45, 106]
–18	Alcohol dehydration ($-H_2O$)	+10.6	2.08 ^c [17]	[17]
	Oxidative dechlorination ($-Cl+OH$)	+33.9	0.73 [146]	[146]
	Reductive defluorination ($-F+H$)	+9.4	–	[147]
–16	Desulfuration ($-S+O$)	+22.8	0.54 [68]	[68]
	Reduction of sulfoxide to thioether ($-O$)	+5.1	–	[113]
	Reduction of hydroxylamine to amine ($-O$)	+5.1	–	[113]
–14	O-demethylation ($-CH_3$)	–15.7	0.88, 0.93 [19]; 0.56, 0.64 [40]; 0.59 [129]; 0.87, 0.88, 0.90 [130]	[19, 25, 40, 46, 108, 129–131]
	N-demethylation ($-CH_3$)	–15.7	0.82 [52]; 0.84 [135]; 0.87 [51]; 0.88 [19]; 0.90 [40]; 0.92 [133]; 0.95 [130]; 0.99 [45]	[19, 40, 45, 47, 50–52, 130, 133, 135, 136]
–6	S-demethylation ($-CH_3$)	–15.7	–	[132]
	Aromatization of saturated ring ($-H_6$)	–47.0	–	[152]
–2	Alcohol oxidation to ketone/aldehyde ($+H_2$)	–15.7	1.01 [83]	[83, 106]
	Ring formation ($-H_2$)	–15.7	1.20 [112]	[112]
	Oxidative defluorination ($-F+OH$)	+4.3	–	[77, 147]
–1	Oxidative deamination to ketone/aldehyde ($-NH_3+O$)	–31.6	–	[142]
+1	Oxidative deamination to alcohol ($-NH+O$)	–16.0	–	[113]
	Hydrolysis of amide to carboxyl ($-NH+O$)	–16.0	–	[143]
+2	Ketone/aldehyde reduction to alcohol ($+H_2$)	+15.7	0.72 [56]; 0.70 [40]	[33, 40, 56, 126]
	Hydrogenation ($+H_2$)	+15.7	1.13 [124]	[17, 124]
	Ring opening ($+H_2$)	+15.7	0.59 [149]	[47, 149–151]

Table 1 (continued)

Nominal mass shift (Δ Da)	Metabolic reaction (elemental composition change)	Exact mass shift (mDa)	Examples of relative retention shift ^a	References
	Methyl/methylene oxidation to aldehyde/ketone ($+O-H_2$)	–20.7	0.92, 1.02 [102]; 1.05 [45]	[45, 102]
	Alcohol oxidation to carboxylic acid ($+O-H_2$)	–20.7	–	[106]
	Hydroxylation and cyclization ($+O-H_2$)	–20.7	–	[106]
	Hydroxylation ($+O$)	–5.1	0.38 [51]; 0.40 [131]; 0.46 [23, 24, 40, 45, 137]; 0.46, 0.50, 0.62 [47, 51, 52, 76, 124]; 0.51, 0.73, 0.82 [83, 102, 108]	[47, 51, 52, 76, 124, 130, 131, 132, 133]
			0.89, 0.96 [76]; 0.56 [40]; 0.58 [135]; 0.60, 0.62 [112]; 0.61 [45]; 0.69 [130]; 0.80 [52]; 0.82 [138]; 0.85 [102]	[40, 45, 51, 112, 124, 130, 131, 132, 133]
	Epoxidation ($+O$)	–5.1	0.56 [124]; 0.72 [140]; 0.89 [77]	[77, 124, 140, 141]
	N-oxidation ($+O$)	–5.1	0.93 [40]; 1.04 [45]; 1.09 [76]	[40, 45, 51, 76, 131, 136]
	S-oxidation of thioether to sulfoxide or sulfide ($+O$)	–5.1	0.34 (S-SO) [141]; 0.82 (S-SO) [138]; 1.02 (SO-SO ₂) [143]	[138, 141, 143]
	S-oxidation of thioether to sulfone ($+O$)	–5.1	–	[126]
	Aldehyde oxidation to carboxyl ($+O$)	–5.1	–	
	Oxidation and ring formation ($+O$)	–5.1	0.46, 0.51 [137]; 0.53, 0.64 [80]	[80, 137]
	Ring opening by water addition ($+H_2O$)	+10.6	1.10 [18]	[18, 19]
	Hydrolysis of nitrile to amide ($+H_2O$)	+10.6	–	[45]
	Methyl oxidation to carboxylic acid ($+O_2-H_2$)	–25.8	0.24 [167]; 0.34 [40]	[40, 50, 167]
	Dihydroxylation ($+O_2$)	–10.2	0.49 [54]; 0.39 [124]; 0.80, 0.81 [160]; 0.84 [83]; 0.63, 0.67, 0.71, 0.79, 0.94 [76]	[54, 76, 83, 124, 160]
	S-oxidation of thioether to sulfone ($+O_2$)	–10.2	0.79 [138]	[138]
	Epoxidation and hydration ($+H_2O_2$)	+5.5	0.39 [124]; 0.47 [140]; 0.51, 0.68 [141]	[124, 140, 141]
	Trihydroxylation ($+O_3$)	–15.3	–	[113]
	S-oxidation of thiol to sulfonic acid ($+O_3$)	–15.3	–	[113]

^aThe parent drug has a relative retention shift (RRS) of 1.00.

^bThe value of x corresponds to the length of the alkyl chain.

^cRRS is related to another metabolite.

Biotransformation list

M1

M2-M6 Conjugation of Epicatechin

M7-M9 C-Ring Cleavage of Epicatechin

M10-M11
Phenylvalerolactone
Metabolites

M12-M13
Phenylvalenic Acid
Metabolites

M14-M20
Phenylpropionic Acid
Metabolites

M21-M23 Phenylacetic Acids Metabolites

M24-M27
Benzoic Acid Metabolites









FIGURE 5 | The proposed metabolic pathway of 45 identified metabolites of procyandin B2 in mice.

Isotopic filtering

Discriminate metabolites based on characteristic isotopic pathway



Conjugated metabolites



- Used as post-acquisition data processing tool
- Less recommended triggering DDA experiments

Mass defect filter


Proposed metabolites of Atrazine (ATZ)

DEALKYLATED METABOLITES
 DACT, diaminochlorotriazine
 DEA, desethylatrazine
 DIA, desisopropyl atrazine

HYDROXYLATED METABOLITES
 ATZ-OH, hydroxyatrazine
 DEA-OH, hydroxydesethylatrazine
 Ammieline

GLUTATHIONE-DERIVED MERCAPTURIC ACID
 AM, atrazine mercapturate
 DEAM, desethylatrazine mercapturate
 DIAM, desisopropylatrazine mercapturate
 DATM, diaminotriazine mercapturate

ID	Description of the Biotransformation	Nominal Mass shift (Da)
AM	Dechlorination Mercapturic acid conj.	127
DEAM	Dechlorination Mercapturic acid conj. N-dealkylation	99
DIAM	Dechlorination Mercapturic acid conj. N-dealkylation	85
DATM	Dechlorination Mercapturic acid conj. N-dealkylation	57
DEA	N-dealkylation	-28
DIA	N-dealkylation	-42
DACT	N-dealkylation	-70
ATZ-OH	Oxidative dechlorination	-18
DEA-OH	N-dealkylation & Oxidative dechlorination	-46
Ammieline	N-dealkylation & Oxidative dechlorination	-88



Mass defect filter

Mass Defect Filter (MDF)

Difference between the exact mass of an element (or a compound) and its closest integer value


- Used as post-acquisition data processing tool
- Some software consider MDF filtering accordingly to predicted cleavage products

ID	Description of the Biotransformation	Formula Change	Nominal Mass shift (Da)	Accurate Mass Shift (Da)	Mass Defect (mDa)
AM	Dechlorination Mercapturic acid conj.	-Cl, +C5H8NO3S	127	127.0536	53.6
DEAM	Dechlorination Mercapturic acid conj. N-dealkylation	-Cl, +C3H4NO3S	99	99.0223	22.3
DIAM	Dechlorination Mercapturic acid conj. N-dealkylation	-Cl, +C2H2NO3S	85	85.0067	6.7
DATM	Dechlorination Mercapturic acid conj. N-dealkylation	-ClH ₂ , +NO3S	57	56.9754	-24.6
ATZ-OH	Oxidative dechlorination	-Cl, +HO	-18	-17.9661	33.9
DEA	N-dealkylation	-C ₂ H ₄	-28	-28.0313	-31.3
DIA	N-dealkylation	-C ₃ H ₆	-42	-42.0470	-47.0
DEA-OH	N-dealkylation & Oxidative dechlorination	-CIC ₂ H ₃ , +O	-46	-45.9974	2.6
DACT	N-dealkylation	-C ₅ H ₁₀	-70	-70.0783	-78.3
Ammieline	N-dealkylation & Oxidative dechlorination	-CIC ₅ H ₉ , +O	-88	-88.0444	-44.4

MS/MS data interpretation


While assigning the structures, some software predict the theoretical fragments for the parent drug and metabolites, and assign/compares them with experimentally obtained MS/MS results

In absence of standard structural assignments are always tentative



Cross species comparison


- Identify human metabolites that differ from those observed in animal models, assisting pre-clinical safety and toxicity studies
- inter-species metabolic stability assessment should be considered in study design



Cross species comparison

Peak Area is not necessarily proportional to analyte abundance, but it's associated to ionization efficiency of each analyte

In some cases the addition of complementary UV detection is sufficient for metabolite quantification



Conclusions

Take-home messages

- Study outcomes should meet stage-based needs
- LC-HRMS is the technique of choice
- Data processing is still the most demanding step
- Use customised processing workflow
- In absence of standards or complementary detection techniques mass spectrometry is not quantitative


QUESTIONS
AND ANSWERS



Your contact:

Business Development
114 Innovation Drive, Milton Park, Abingdon
Oxfordshire OX14 4RZ, UK

T: +44.(0)1235.86 15 61
F: +44.(0)1235.86 31 39
info@evotec.com



Your contact:

Maria Anna Fedrigo
Research Expert, Discovery DMPK

+39 045 8218325
+39 045 8218153 Fax
Maria.Fedrigo@Aptuit.com

